Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Wanxing Chai Ho
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Wanxing Chai Ho
HS Assistant Clinical Professor, Medicine. Authored (or co-authored) 13 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Syros Pharmaceuticals
- Links
- Sign up for this study
- ID
- NCT04797780
- Phase
- Phase 3 Myelodysplastic Syndrome Research Study
- Study Type
- Interventional
- Participants
- Expecting 550 study participants
- Last Updated